- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Ariad Pharmaceuticals Inc
+ Add to WatchlistARIA:US
18.4300 USD 0.9000 5.13%As of 20:10:00 ET on 05/22/2013.
Snapshot for Ariad Pharmaceuticals Inc (ARIA)
| Open: | 17.6300 | Day's Range: | 17.6000 - 19.6400 | Volume: | 8,155,568 |
|---|---|---|---|---|---|
| Previous Close: | 18.4300 | 52wk Range: | 15.1300 - 25.4000 | 1-Yr Rtn: | +9.64% |
Key Statistics for ARIA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.3312 |
| Est. EPS (USD) (12/2013) | -1.6460 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 3,403.85 |
| Shares Outstanding (M) | 184.69 |
| 30 Day Average Volume | 3,104,725 |
| Price/Book (mrq) | 9.3448 |
| Price/Sale (ttm) | 471.6327 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ARIA
Company Profile & Key Executives for ARIA
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant or difficult-to-treat cancers.
| Harvey J BergerChairman/Pres/CEO | Timothy P ClacksonPresident:Research & Develpmnt |
| Edward M FitzgeraldExec VP/CFO/Treasurer | David L BersteinSenior VP/Chief Intellectual |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ARIA News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page